Efficacy and safety of degludec/liraglutide combination injection switching from basal insulin therapy with the DPP-4 inhibitor in Japanese type 2 diabetic patients
Not Applicable
- Conditions
- Type 2 diabets
- Registration Number
- JPRN-UMIN000038667
- Lead Sponsor
- Fujisawa City Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with insulin therapy except basal insulin 2. Patients with GLP-1 receptor agonist 3. Patients with severe liver dysfunction 4. Patients with severe infection, operation, trauma 5. Patients with steroid medication 6. Patient with erythropoietin therapy 7. Patients with malignant tumors 8. Patients who have pregnancy or possibilty of pregnancy, or are under lactation 9. Patients who have hypersensitivity to insulin degludec, liraglutide, or teneligliptin 10. Patients who are considered to be not eligible to the study by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparing the two groups change in HbA1c over the 24-week treatment period
- Secondary Outcome Measures
Name Time Method 1. Fasting plasma glucose 2. Body weight 3. creatinine 4. eGFR 5. Urine albumin/creatinine ratio 6. Lipid profile 7. Insulin dose 8. Frequency of hypoglycemia 9. Other adverse event